17 results
Primary Objective: The primary objective is to determine whether the administration of Gelofusine will reduce the kidney uptake of 111In-labeled exendin in humans by enhancing the excretion of 111In-labeled exendin. These highly relevant data can…
The primary objective is to compare GLP-1R-imaging to standard imaging techniques now used in pre-operative imaging of patients with AHH. All patients will undergo the standard imaging procedures of the specific centre and in addition we will…
Onset of effect of systemic therapy to enhance bone density (eg, bisphosphonates) is not immediate and may not adequately protect subjects with decreased bone density from fracture.Bisphosphonate therapy will typically require 2 to 3 years of active…
1. To study the rate of change of diastolic and systolic LV function and LV structure, and the incidence of heart failure over a 7-year period in subjects with and without DM2 2. To study the potential determinants of accelerated deterioration of LV…
The main study aim is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of children (< 16 years) with proven endogenous congenital hyperinsulinism who qualify for surgery based on response…
The objective of this pilot study is to investigate if glucose measurement on the vaginal wall can be an alternative for capillary and subcutaneous glucose measurement. The present study will look at the efficacy of an intravaginal device to measure…
The study objective is to compare the pituitary uptake of 68Ga-NODAGA-exendin in patients with and without adequate response (based on HbA1c or weight loss or classification by the treating diabetologist) to GLP-1R agonist treatment, to increase…
The primary objective of this study is to assess if clinically relevant changes occur in fat free mass (FFM) between baseline and follow up six months after the end of treatment. Our cut-off value of a clinically relevant difference in body…
We aim to determine the specificity of radiolabelled exendin during the course of T2D and to examine the role of glycemic control on the correlation between pancreatic 111In-exendin uptake, BCM and GLP-1R expression in patients with T2D undergoing (…
The primairy objective of this study is to investigate whether beta cell mass is correlated to beta cell function after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type 1 diabetes after FMT. Within 1 month…
Primary Objective: Compare the uptake of 68Ga-NODAGA-exendin-4 in the liver between T1D patients with functional islet grafts (C-peptide > 0.8 nmol/L after mixed meal stimulation test and relevant laboratory parameters as HbA1C and exogenous…
The study objective is to measure beta cell mass and function in subjects with type 1 diabetes during and shortly after the honeymoon phase, to determine whether the change in metabolic control is mainly caused by a decrease in the total number of…
The main study objective is to measure residual beta cell mass, indicated by the pancreatic uptake of Ga-68-exendin using quantitative PET, in type 1 diabetes patients with stable near-normal and unstable glucose control, to improve understanding of…
The objective of this pilot study is to investigate the efficiency of a glucose monitor device placed in a tear fluid of human eye to measure glucose for up to 6 hours and its correlation to blood glucose values. Additionally, more information will…
This study has been transitioned to CTIS with ID 2024-520392-27-00 check the CTIS register for the current data. The primary objective is to evaluate the difference in 68Ga-exendin tracer accumulation in the pancreas of women with and without a…
The objective of this pilot study is to investigate the efficiency of a glucose monitor device placed in a tear fluid of human eye to measure glucose for up to 5 hours and its correlation to blood glucose values. Additionally, more information will…
The main study aim is the in vivo and ex vivo investigation of the expression and distribution of the GLP-1R in the pancreas of children (< 16 years) with proven endogenous congenital hyperinsulinism who qualify forsurgery based on response…